The subsequent treatment involved intensive procedures, including five rounds of chemotherapy, external beam radiation, and ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to M2T-CD33 (LTI-214) for the treatment of ...

Caregivers must respect the autonomy of adult patients, balancing support with allowing them to lead their own cancer journey ...

While October promotes awareness through campaigns, ribbons and fundraising, survivors report a more complex reality. Breast cancer survivor Maureen Green described the month as a reminder of the ...

CURE had the privilege of attending the Hairy Cell Leukemia Foundation 2025 Conference in Bologna, Italy, where medical experts gathered to discuss advances in research, treatment ...

“Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers,” by Dewpoint Therapeutics. News release; Oct. 21, 2025. For more news on cancer ...

PhD in clinical psychology. She is a senior psychologist, director of Interprofessional Education and director of the Young Adult Program (YAP) in the Department of Supportive Oncology at Dana-Farber ...

CURE attended the Hairy Cell Leukemia Foundation 2025 Conference where medical experts gathered to discuss advances in research and patient care.

HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...

Longer-term trial results show Voranigo may help control grade 2 IDH-mutated glioma after surgery for those who can delay ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

Stage 2 cervical cancer is classified into 2A and 2B, based on tumor spread and size, affecting treatment decisions.